The production line of human avian influenza vaccine is ready in Beijing

Introduction: Yin Weidong, general manager of Beijing Kexing Biological Products Co., Ltd., which is responsible for the research and development of human avian influenza vaccine in China, told reporters Monday that at present, the production line of human avian influenza vaccine has been prepared in Beijing After the completion of all clinical trials of the vaccine, or in case of emergency, with the approval of relevant national departments, the production line can be put into production immediately On October 21, Beijing Kexing Biological Products Co., Ltd submitted an application for clinical research to the State Food and drug administration If approved, the vaccine will enter the clinical research Once production is decided, after a 128 day production cycle, vaccine products can be produced It is expected that the product price will be lower than the current seasonal influenza vaccine price Yin Weidong said that in March 2004, when the first outbreak of avian influenza occurred in China, the subject of "research and development of human avian influenza vaccine" was established, and decided to be jointly undertaken by Beijing Kexing Biological Products Co., Ltd and China Center for Disease Control and prevention The research team obtained the strains of human avian influenza vaccine from the World Health Organization influenza central laboratory "If we find a mutation of avian influenza virus, we can complete the transformation of the virus within 48 days and develop a new vaccine within 4 months." Yin Weidong said that at present, there are 8 vaccine research and development institutions in the world that are developing human avian influenza vaccine, which are mainly concentrated in European and American countries, and the vaccine development is in the clinical research and development stage It is understood that Beijing Kexing is a biotechnology company specializing in the research, development and sales of human vaccines The company has successfully developed the SARS vaccine The company was founded in 2001 in Beijing Zhongguancun High Tech Park, Beida biological city.